Updates are available Correction dated 2023-09-18
Click to view Correction: https://doi.org/10.1038/s41590-023-01646-3
-
Authors
Proal, Amy D. https://orcid.org/0009-0001-9495-8572
VanElzakker, Michael B.
Aleman, Soo
Bach, Katie
Boribong, Brittany P. https://orcid.org/0000-0003-1297-6337
Buggert, Marcus https://orcid.org/0000-0003-0633-1719
Cherry, Sara https://orcid.org/0000-0003-3956-6610
Chertow, Daniel S. https://orcid.org/0000-0002-1675-1728
Davies, Helen E. https://orcid.org/0000-0001-6102-256X
Dupont, Christopher L. https://orcid.org/0000-0002-0896-6542
Deeks, Steven G.
Eimer, William
Ely, E. Wesley
Fasano, Alessio
Freire, Marcelo https://orcid.org/0000-0003-4906-7698
Geng, Linda N.
Griffin, Diane E.
Henrich, Timothy J.
Iwasaki, Akiko https://orcid.org/0000-0002-7824-9856
Izquierdo-Garcia, David
Locci, Michela
Mehandru, Saurabh https://orcid.org/0000-0001-9781-2969
Painter, Mark M. https://orcid.org/0000-0002-0180-2748
Peluso, Michael J.
Pretorius, Etheresia
Price, David A. https://orcid.org/0000-0001-9416-2737
Putrino, David
Scheuermann, Richard H. https://orcid.org/0000-0003-1355-892X
Tan, Gene S.
Tanzi, Rudolph E. https://orcid.org/0000-0002-7032-1454
VanBrocklin, Henry F.
Yonker, Lael M. https://orcid.org/0000-0003-1711-8227
Wherry, E. John https://orcid.org/0000-0003-0477-1956
-
Funding
Funding for this research was provided by:
PolyBio Research Foundation
- License Information
-
More Information
Article History
Received: 30 March 2023
Accepted: 18 July 2023
First Online: 4 September 2023
Change Date: 18 September 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41590-023-01646-3
Competing interests
: A.D.P. has received consulting fees from Enanta Pharmaceuticals outside the submitted work. S.A. has received honoraria for lectures and educational events from Gilead, AbbVie, MSD and Biogen, and reports grants from Gilead and AbbVie. E.W.E. has received grant support/research funding from the US National Institutes of Health and Veterans Administration, is an unfunded investigator with baricitinib on COVID-19 studies funded by Eli Lilly, and has lectured at events related to sedation in the intensive care unit sponsored by Pfizer. M.F. reports a relationship with Mars that includes board membership. L.N.G. reports receiving grants from Pfizer and advisory fees from UnitedHealthcare. D.E.G. is a member of the scientific advisory committees for GSK, Merck and Takeda Pharmaceuticals. T.J.H. consults for Roche and received grant support from Merck. A.I. cofounded and consults for RIGImmune, Xanadu Bio and PanV; consults for Paratus Sciences, InvisiShield Technologies; and is a member of the Board of Directors of Roche Holding. M.J.P. has received consulting fees from Gilead Sciences and AstraZeneca, outside the submitted work. E.P. founded Biocode Technologies and holds a patent for detection of microclots in blood samples. E.J.W. is a member of the Parker Institute for Cancer Immunotherapy, which supports cancer immunology research in the laboratory of E.J.W. E.J.W. is an advisor for Danger Bio, Janssen, New Limit, Marengo, Pluto Immunotherapeutics, Related Sciences, Santa Ana Bio, Synthekine and Surface Oncology. E.J.W. is a founder of and holds stock in Surface Oncology, Danger Bio and Arsenal Biosciences.
